A practical reference on thymosin alpha-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Finally, Alexander Shulgin has suggested that nutmeg might be a serotonergic psychedelic via conversion of active constituents into psychedelic amphetamines along with toxic effects from other constituents, though this has not been supported. Nutmeg intoxication has also been confused with those of phencyclidine (PCP) and alcohol as well as likened in some respects to that of alcohol. A clinical study of an isolated fraction of nutmeg that appears to have contained a mixture of myristicin, elemicin, and perhaps a small amount of methylisoeugenol was conducted and published in 1961. A dose of 400 mg of the mixture (equivalent to about 40 g whole nutmeg) was given orally. It produced symptoms suggestive of psychoactive effects such as mild stimulation in 6 of 10 individuals and definite psychoactive effects in 4 of 10 individuals, but failed to exactly reproduce the intoxication characteristic of nutmeg. Effects included euphoria, restlessness, weakness, nervousness, tremor, anxiety, tachycardia, gastrointestinal discomfort, nausea, and others. In the same study, it was found that 10 grams nutmeg with the volatile compounds removed produced no psychoactive effects but did cause in some instances undesirable side effects. It has been suggested that there might be a synergy between myristicin and other nutmeg constituents, for instance other individual allylbenzenes. Alternatively, other constituents may be responsible for the psychoactive and hallucinogenic effects instead. Shulgin reported one other constituent, methoxyeugenol, to be inactive at doses of up to 10 mg orally.
=== Therapeutics === Because it is abundant, of human origin, and easy to grow, L. plantarum has been tested for health effects. It has been identified as a probiotic, which suggests its value for further research and application. L. plantarum has significant antioxidant activities and also helps to maintain intestinal permeability. It is able to suppress the growth of gas-producing bacteria in the intestines and may benefit some patients who suffer from IBS. It helps to create microbe balance and stabilize digestive enzyme patterns. Lactiplantibacillus plantarum has been found in experiments to increase hippocampal brain derived neurotrophic factor, which means L. plantarum may have a beneficial role in the treatment of depression. The ability of L. plantarum to survive in the human gastro-intestinal tract makes it a possible in vivo delivery vehicle for therapeutic compounds or proteins. Lactiplantibacillus plantarum is a constituent in VSL#3. This proprietary, standardized formulation of live bacteria may be used in combination with conventional therapies to treat ulcerative colitis and requires a prescription.
=== England === It has been argued by historians that, in the sixteenth century, England came to pursue a foreign policy which would preserve the equilibrium between Spain and France, which evolved into a balance-of-power policy:
In 1972, having not yet received a full position, Leeman returned to Harvard Medical School as an assistant professor and continued her studies of substance P and neurotensin in the Laboratory of Human Reproduction and Reproductive Biology until 1980. She then left the medical school when she realised that she would not be offered a tenure there either, gaining a tenured professorship in physiology at the University of Massachusetts Medical School. In 1992, Leeman left Massachusetts to help start the pharmacology department at Boston University, where she has remained a professor in the Department of Pharmacology & Experimental Therapeutics, and the director of the Neuropeptide Laboratory in the Pharmacology Department at the Chobanian and Avedisian School of Medicine. As a result of her work Leeman is widely regarded as one of the founders of the field of neuroendocrinology.
Sources: en.wikipedia.org
== Choice of base formulation == A medication's potency often is changed with its base. For example, some topical steroids will be classified one or two strengths higher when moving from cream to ointment. As a rule of thumb, an ointment base is more occlusive and will drive the medication into the skin more rapidly than a solution or cream base. The manufacturer of each topical product has total control over the content of the base of a medication. Although containing the same active ingredients, one manufacturer's cream might be more acidic than the next, which could cause skin irritation or change its absorption rate. For example, a vaginal formulation of miconazole antifungal cream might irritate the skin less than an athlete's foot formulation of miconazole cream. These variations can, on occasion, result in different clinical outcomes, even though the active ingredient is the same. No comparative potency labeling exists to ensure equal efficacy between brands of topical steroids (percentage of oil vs water dramatically affect the potency of topical steroid). Studies have confirmed that the potency of some topical steroid products may differ according to manufacturer or brand. An example of this is the case of brand name Valisone cream and Kenalog cream in clinical studies have demonstrated significantly better vasoconstrictions than some forms of this drug produced by generic drug manufacturers. However, in a simple base like an ointment, much less variation between manufacturers is common.
=== Scientific journal articles === Holick, MF (2007). "Vitamin D deficiency". N Engl J Med. 357 (3): 266–81. doi:10.1056/NEJMra070553. PMID 17634462. S2CID 18566028. Holick, MF (2006). "Resurrection of vitamin D deficiency and rickets". J Clin Invest. 116 (8): 2062–72. doi:10.1172/JCI29449. PMC 1523417. PMID 16886050. Pietras, SM; Obayan, BK; Chai, MH; Holick, MF (2010). "Vitamin D2 treatment for vitamin D deficiency and insufficiency for up to 6 years". Arch Intern Med. 169 (19): 1806–8. doi:10.1001/archinternmed.2009.361. PMID 19858440. Biancuzzo, RM; Young, A; Bibuld, D; Cai, MH; Winter, RM; Klein, EK; Ameri, A; Reitz, R; Salameh, W; Chen, TC; Holick, MF (2010). "Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults". Am J Clin Nutr. 91 (6): 1621–6. doi:10.3945/ajcn.2009.27972. PMC 2869510. PMID 20427729. Holick, MF; Binkley, NC; Bischoff-Ferrari, HA; Gordon, CM; Hanley, DA; Heaney, RP; Murad, MH; Weaver, CM; et al. (2011). "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (7): 1911–30. doi:10.1210/jc.2011-0385. PMID 21646368.
Difenoxin (Motofen, R-15403) is an opioid drug used, often in combination with atropine, to treat diarrhea. It is the principal metabolite of diphenoxylate. It was first approved in the US in 1978 and in 1980 in the former West Germany. Difenoxin crosses the blood brain barrier and induces some euphoria; it is often sold with or administered with atropine to reduce the potential for abuse and overdose.
== See also == Substituted methoxyphenethylamine Scaline § Related compounds Dimethoxyphenethylamine 3-Methoxytyramine Mescaline 3-Methoxy-4-ethoxyphenethylamine (MEPEA; 3-desmethoxyescaline) 3-Methoxy-4-allyloxyphenethylamine (MAPEA; 3-desmethoxyallylescaline) Pachycereus pringlei § Constituents and effects
== Facilities == The Fat Duck has 14 tables and can seat 42 diners. It has a high proportion of chefs working, 42, equating to one chef per diner. Much of the menu is developed by experimentation: for example, the egg and bacon ice cream came about following Blumenthal investigating the principles of "flavour encapsulation". A research laboratory where Blumenthal and his team develop dishes is two doors away opposite the Hind's Head pub, which he also owns. It was where the majority of the laboratory scenes for the television series Heston Blumenthal: In Search of Perfection were filmed. The lab equipment includes a centrifuge which is used to make chocolate wine, and a vacuum oven. The restaurant takes reservations up to two months in advance, and in 2011 it was receiving some 30,000 calls for reservations per day, although that figure also included people who could not get through and were redialling.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.